Prognostic Impact of Soluble P-Selectin on Long-Term Adverse Cardiovascular Outcomes in Patients Undergoing Percutaneous Coronary Intervention

Maximilian Tscharre; Birgit Vogel; Ioannis Tentzeris; Matthias K. Freynhofer; Miklos Rohla; Johann Wojta; Thomas W. Weiss; Cihan Ay; Kurt Huber; Serdar Farhan

doi:10.1055/s-0038-1676563

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2019; 119(02): 340-347
DOI: 10.1055/s-0038-1676563

Atherosclerosis and Ischaemic Disease

Georg Thieme Verlag KG Stuttgart · New York

Prognostic Impact of Soluble P-Selectin on Long-Term Adverse Cardiovascular Outcomes in Patients Undergoing Percutaneous Coronary Intervention

Maximilian Tscharre

¹3rd Medical Department, Cardiology and Intensive Care Medicine, Wilhelminenspital, Vienna, Austria

²Institute for Cardiometabolic Diseases, Karl Landsteiner Society, St. Pölten, Austria

,

Birgit Vogel

¹3rd Medical Department, Cardiology and Intensive Care Medicine, Wilhelminenspital, Vienna, Austria

³The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New York, United States

,

Ioannis Tentzeris

¹3rd Medical Department, Cardiology and Intensive Care Medicine, Wilhelminenspital, Vienna, Austria

,

Matthias K. Freynhofer

¹3rd Medical Department, Cardiology and Intensive Care Medicine, Wilhelminenspital, Vienna, Austria

⁴Sigmund Freud University Medical School, Sigmund Freud University, Vienna, Austria

,

Miklos Rohla

¹3rd Medical Department, Cardiology and Intensive Care Medicine, Wilhelminenspital, Vienna, Austria

²Institute for Cardiometabolic Diseases, Karl Landsteiner Society, St. Pölten, Austria

,

Johann Wojta

⁵Division of Cardiology, Department of Internal Medicine 2, Medical University of Vienna, Vienna, Austria

⁶Core Facilities, Medical University of Vienna, Vienna, Austria

⁷Ludwig Boltzmann Cluster for Cardiovascular Research, Vienna, Austria

,

Thomas W. Weiss

¹3rd Medical Department, Cardiology and Intensive Care Medicine, Wilhelminenspital, Vienna, Austria

²Institute for Cardiometabolic Diseases, Karl Landsteiner Society, St. Pölten, Austria

⁴Sigmund Freud University Medical School, Sigmund Freud University, Vienna, Austria

,

Cihan Ay

⁸Clinical Division of Haematology and Haemostaseology, Department of Medicine 1, Medical University of Vienna, Vienna, Austria

⁹I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia

,

Kurt Huber

¹3rd Medical Department, Cardiology and Intensive Care Medicine, Wilhelminenspital, Vienna, Austria

⁴Sigmund Freud University Medical School, Sigmund Freud University, Vienna, Austria

,

Serdar Farhan

¹3rd Medical Department, Cardiology and Intensive Care Medicine, Wilhelminenspital, Vienna, Austria

³The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New York, United States

› Author Affiliations

Abstract

Background Soluble P-selectin (sP-selectin), a biomarker of inflammatory pathologies including cardiovascular disease, is known to have pro-atherosclerotic effects such as the ability to increase leukocyte recruitment and modulate thrombotic response. We aimed to assess the impact of sP-selectin on long-term major adverse cardiovascular events (MACE) in patients after coronary stenting for coronary artery disease.

Methods We analysed 733 patients of a single-centre registry undergoing percutaneous coronary intervention (PCI) between 2003 and 2006. Plasma samples were analysed for sP-selectin antigen concentration with an enzyme-linked immunoassay. The study population was categorized according to sP-selectin quartiles. Endpoint of the study was long-term MACE, a composite of all-cause death, myocardial infarction (MI) and stroke.

Results Of the total patient cohort, 361 (49.2%) patients were admitted for stable coronary artery disease and 372 (50.8%) for acute coronary syndrome. Median age was 64 years and 70.7% were male. After a mean follow-up period of 9.7 years, MACE occurred in 344 (46.9%) patients. The primary endpoint components of all-cause death occurred in 211 (28.8%), MI in 88 (12.0%) and ischaemic stroke in 45 (6.1%) patients. After adjustment for confounders, patients in the 2nd, 3rd and 4th quartile were at higher risk for MACE compared with the 1st quartile (hazard ration [HR], 1.234 [0.899–1.695], p = 0.193; HR, 1.480 [1.085–2.019], p = 0.013; and HR, 1.571 [1.115–2.152], p = 0.004). sP-selectin as continuous variable model was significantly associated with MACE after adjustment (HR per 1 ng/mL increase of 1.009 [95% confidence interval, 1.002–1.017]; p = 0.016).

Conclusion Elevated levels of sP-selectin were associated with increased risk for long-term MACE in patients undergoing PCI.

Keywords

soluble P-selectin - percutaneous coronary intervention - long-term major adverse cardiovascular outcome

Full Text

References

References
1 World Health Organization. Health statistics and information systems. Cause-specific mortality. Estimates for 2000. World Heal Stat 2012; 2012: 2012
2 Santos-Gallego CG, Picatoste B, Badimón JJ. Pathophysiology of acute coronary syndrome. Curr Atheroscler Rep 2014; 16 (04) 401
3 Stenberg PE, McEver RP, Shuman MA, Jacques YV, Bainton DF. A platelet alpha-granule membrane protein (GMP-140) is expressed on the plasma membrane after activation. J Cell Biol 1985; 101 (03) 880-886
4 McEver RP, Beckstead JH, Moore KL, Marshall-Carlson L, Bainton DF. GMP-140, a platelet alpha-granule membrane protein, is also synthesized by vascular endothelial cells and is localized in Weibel-Palade bodies. J Clin Invest 1989; 84 (01) 92-99
5 Blann AD, Nadar SK, Lip GYH. The adhesion molecule P-selectin and cardiovascular disease. Eur Heart J 2003; 24 (24) 2166-2179
6 Zhang N, Liu Z, Yao L, Mehta-D'souza P, McEver RP. P-selectin expressed by a human SELP transgene is atherogenic in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 2016; 36 (06) 1114-1121
7 Mayadas TN, Johnson RC, Rayburn H, Hynes RO, Wagner DD. Leukocyte rolling and extravasation are severely compromised in P selectin-deficient mice. Cell 1993; 74 (03) 541-554
8 Ramos CL, Huo Y, Jung U. , et al. Direct demonstration of P-selectin- and VCAM-1-dependent mononuclear cell rolling in early atherosclerotic lesions of apolipoprotein E-deficient mice. Circ Res 1999; 84 (11) 1237-1244
9 Ishiwata N, Takio K, Katayama M. , et al. Alternatively spliced isoform of P-selectin is present in vivo as a soluble molecule. J Biol Chem 1994; 269 (38) 23708-23715
10 Fox JE. Shedding of adhesion receptors from the surface of activated platelets. Blood Coagul Fibrinolysis 1994; 5 (02) 291-304
11 Woollard KJ, Kling D, Kulkarni S, Dart AM, Jackson S, Chin-Dusting J. Raised plasma soluble P-selectin in peripheral arterial occlusive disease enhances leukocyte adhesion. Circ Res 2006; 98 (01) 149-156
12 Woollard KJ, Suhartoyo A, Harris EE. , et al. Pathophysiological levels of soluble P-selectin mediate adhesion of leukocytes to the endothelium through Mac-1 activation. Circ Res 2008; 103 (10) 1128-1138
13 Woollard KJ, Lumsden NG, Andrews KL. , et al. Raised soluble P-selectin moderately accelerates atherosclerotic plaque progression. Ma X-L. , ed. PLoS One 2014. 9: e97422
14 Kisucka J, Chauhan AK, Zhao B-Q. , et al. Elevated levels of soluble P-selectin in mice alter blood-brain barrier function, exacerbate stroke, and promote atherosclerosis. Blood 2009; 113 (23) 6015-6022
15 André P, Hartwell D, Hrachovinová I, Saffaripour S, Wagner DD. Pro-coagulant state resulting from high levels of soluble P-selectin in blood. Proc Natl Acad Sci U S A 2000; 97 (25) 13835-13840
16 Blann AD, McCollum CN. Increased soluble P-selectin in peripheral artery disease: a new marker for the progression of atherosclerosis. Thromb Haemost 1998; 80 (06) 1031-1032
17 Varughese GI, Patel JV, Tomson J, Blann AD, Hughes EA, Lip GY. Prognostic value of plasma soluble P-selectin and von Willebrand factor as indices of platelet activation and endothelial damage/dysfunction in high-risk patients with hypertension: a sub-study of the Anglo-Scandinavian Cardiac Outcomes Trial. J Intern Med 2007; 261 (04) 384-391
18 Ay C, Simanek R, Vormittag R. , et al. High plasma levels of soluble P-selectin are predictive of venous thromboembolism in cancer patients: results from the Vienna Cancer and Thrombosis Study (CATS). Blood 2008; 112 (07) 2703-2708
19 Ay C, Jungbauer LV, Sailer T. , et al. High concentrations of soluble P-selectin are associated with risk of venous thromboembolism and the P-selectin Thr715 variant. Clin Chem 2007; 53 (07) 1235-1243
20 Dunkler D, Plischke M, Leffondré K, Heinze G. Augmented backward elimination: a pragmatic and purposeful way to develop statistical models. PLoS One 2014; 9 (11) e113677
21 Bursac Z, Gauss CH, Williams DK, Hosmer DW. Purposeful selection of variables in logistic regression. Source Code Biol Med 2008; 3: 17
22 Levey AS, Stevens LA, Schmid CH. , et al; CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration). A new equation to estimate glomerular filtration rate. Ann Intern Med 2009; 150 (09) 604-612
23 Lim HS, Blann AD, Lip GYH. Soluble CD40 ligand, soluble P-selectin, interleukin-6, and tissue factor in diabetes mellitus: relationships to cardiovascular disease and risk factor intervention. Circulation 2004; 109 (21) 2524-2528
24 Bielinski SJ, Berardi C, Decker PA. , et al. P-selectin and subclinical and clinical atherosclerosis: the Multi-Ethnic Study of Atherosclerosis (MESA). Atherosclerosis 2015; 240 (01) 3-9
25 Ridker PM, Buring JE, Rifai N. Soluble P-selectin and the risk of future cardiovascular events. Circulation 2001; 103 (04) 491-495
26 Hillis GS, Terregino C, Taggart P. , et al. Elevated soluble P-selectin levels are associated with an increased risk of early adverse events in patients with presumed myocardial ischemia. Am Heart J 2002; 143 (02) 235-241
27 Zamani P, Schwartz GG, Olsson AG. , et al; Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study Investigators. Inflammatory biomarkers, death, and recurrent nonfatal coronary events after an acute coronary syndrome in the MIRACL study. J Am Heart Assoc 2013; 2 (01) e003103-e003103
28 Mulvihill NT, Foley JB, Murphy RT, Curtin R, Crean PA, Walsh M. Risk stratification in unstable angina and non-Q wave myocardial infarction using soluble cell adhesion molecules. Heart 2001; 85 (06) 623-627
29 Kozinski M, Kubica J, Sukiennik A. , et al. Periprocedural soluble P- and E-selectin levels fail as predictors of clinical restenosis in patients treated with elective coronary stenting. Int J Mol Med 2007; 19 (01) 187-195
30 Malik I, Danesh J, Whincup P. , et al. Soluble adhesion molecules and prediction of coronary heart disease: a prospective study and meta-analysis. Lancet 2001; 358 (9286): 971-976
31 Blann AD, Faragher EB, McCollum CN. Increased soluble P-selectin following myocardial infarction: a new marker for the progression of atherosclerosis. Blood Coagul Fibrinolysis 1997; 8 (07) 383-390
32 Dunlop LC, Skinner MP, Bendall LJ. , et al. Characterization of GMP-140 (P-selectin) as a circulating plasma protein. J Exp Med 1992; 175 (04) 1147-1150
33 Fijnheer R, Frijns CJ, Korteweg J. , et al. The origin of P-selectin as a circulating plasma protein. Thromb Haemost 1997; 77 (06) 1081-1085
34 Bickel C, Rupprecht HJ, Blankenberg S. , et al; AtheroGene Group. Influence of HMG-CoA reductase inhibitors on markers of coagulation, systemic inflammation and soluble cell adhesion. Int J Cardiol 2002; 82 (01) 25-31
35 Romano M, Mezzetti A, Marulli C. , et al. Fluvastatin reduces soluble P-selectin and ICAM-1 levels in hypercholesterolemic patients: role of nitric oxide. J Investig Med 2000; 48 (03) 183-189
36 Tardif J-C, Tanguay J-F, Wright SR. , et al. Effects of the P-selectin antagonist inclacumab on myocardial damage after percutaneous coronary intervention for non-ST-segment elevation myocardial infarction: results of the SELECT-ACS trial. J Am Coll Cardiol 2013; 61 (20) 2048-2055